Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3155 Target Snapshot

5-hydroxytryptamine receptor 7 · SINGLE PROTEIN · Homo sapiens

4,575Compounds
793Assays
48Approved Drugs
4,733.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

5-hydroxytryptamine receptor 7 shows clinical signal disease relevance led by bipolar disorder. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P34969. Start with bipolar disorder, then reuse UniProt P34969 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with bipolar disorder, then reuse UniProt P34969 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
bipolar disorder

5-hydroxytryptamine receptor 7 shows clinical signal disease relevance led by bipolar disorder. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with bipolar disorder because it currently carries clinical signal support. Linked drugs include JNJ-18038683. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats 5-hydroxytryptamine receptor 7 as ChEMBL target CHEMBL3155, mapped to UniProt P34969. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
5-hydroxytryptamine receptor 7
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3155
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P34969
5-hydroxytryptamine receptor 7
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether 5-hydroxytryptamine receptor 7 is the right protein anchor across sources, using UniProt P34969 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why bipolar disorder is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label5-hydroxytryptamine receptor 7
UniProt AccessionP34969
Component TypeProtein
Sequence Length479 aa

5-hydroxytryptamine receptor 7

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as 5-hydroxytryptamine receptor 7, mapped to UniProt P34969. Sequence length is 479 aa.

Mapped IDP34969
Review name5-hydroxytryptamine receptor 7
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

5-hydroxytryptamine receptor 7 shows clinical signal disease relevance led by bipolar disorder. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
bipolar disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugJNJ-18038683
Clinical signal Phase II
major depressive disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugJNJ-18038683
Clinical signal Phase II
migraine disorder
1 linked drug · 1 direct · 1 efficacy
Linked drugLY2590443
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with bipolar disorder because it currently carries clinical signal support. Linked drugs include JNJ-18038683. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebipolar disorder
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

48
Approved
11
Phase III
29
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC50740.0
KI3,668.0
EC50316.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5789483 10.0 Ki 0.1 Preclinical
CHEMBL3289972 10.0 Ki 0.1 Preclinical
CHEMBL39 9.96 Ki 0.11 Clinical
CHEMBL592752 9.81 Ki 0.153 Clinical
CHEMBL5179460 9.77 Ki 0.17 Preclinical
CHEMBL18840 9.7 EC50 0.2 Preclinical
CHEMBL363452 9.7 Ki 0.1995 Preclinical
CHEMBL3290016 9.7 Ki 0.2 Preclinical
CHEMBL605405 9.68 Ki 0.2089 Preclinical
CHEMBL225284 9.66 Ki 0.22 Preclinical
Distribution

pChEMBL Value Distribution

375
5.0
414
5.5
585
6.0
628
6.5
693
7.0
571
7.5
436
8.0
229
8.5
137
9.0
31
9.5
pChEMBL
Approved Drugs

Approved Drugs

CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
Approved 2015
BREXPIPRAZOLE
CHEMBL2105760
Approved 2015
CARIPRAZINE
CHEMBL2028019
Approved 2015
VORTIOXETINE
CHEMBL2104993
Approved 2013
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
Approved 2011
LURASIDONE
CHEMBL1237021
Approved 2010
SILODOSIN
CHEMBL24778
Approved 2008
PALIPERIDONE
CHEMBL1621
Approved 2006
CINACALCET HYDROCHLORIDE
CHEMBL1200776
Approved 2004
ARIPIPRAZOLE
CHEMBL1112
Approved 2002
FROVATRIPTAN SUCCINATE
CHEMBL2138684
Approved 2001
ZIPRASIDONE
CHEMBL708
Approved 2001
KETOTIFEN FUMARATE
CHEMBL1633
Approved 1999
DEXMEDETOMIDINE HYDROCHLORIDE
CHEMBL2106195
Approved 1999
QUETIAPINE
CHEMBL716
Approved 1997
TAMSULOSIN
CHEMBL836
Approved 1997
AZELASTINE HYDROCHLORIDE
CHEMBL1200809
Approved 1996
MIRTAZAPINE
CHEMBL654
Approved 1996
OLANZAPINE
CHEMBL715
Approved 1996
SALMETEROL
CHEMBL1263
Approved 1994
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
Approved 1994
CISAPRIDE
CHEMBL1729
Approved 1993
RISPERIDONE
CHEMBL85
Approved 1993
SUMATRIPTAN
CHEMBL128
Approved 1992
CLOZAPINE
CHEMBL42
Approved 1989
AMISULPRIDE
CHEMBL243712
Approved 1986
BUSPIRONE
CHEMBL49
Approved 1986
AMOXAPINE
CHEMBL1113
Approved 1980
MOLINDONE
CHEMBL460
Approved 1974
CLONIDINE HYDROCHLORIDE
CHEMBL1705
Approved 1974
HALOPERIDOL
CHEMBL54
Approved 1967
METHYSERGIDE
CHEMBL1065
Approved 1962
THIORIDAZINE
CHEMBL479
Approved 1962
CYPROHEPTADINE
CHEMBL516
Approved 1961
FLUPHENAZINE
CHEMBL726
Approved 1959
PERPHENAZINE
CHEMBL567
Approved 1957
CHLORPROMAZINE
CHEMBL71
Approved 1957
DIHYDROERGOTAMINE MESYLATE
CHEMBL1200517
Approved 1946
Assay Landscape

Assay Landscape

793
Total Assays
3,245
Tested Compounds
3
Assay Types
Binding — 651 assays, 3,245 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 360 630 7.0
cell-based format 261 2,090 7.1
assay format 16 398 6.5
cell membrane format 11 121 6.5
tissue-based format 3 6 7.6
Functional — 134 assays, 99 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 116 86 6.4
assay format 10 4 7.6
cell membrane format 4 3 7.8
tissue-based format 4 6 5.6
ADME — 8 assays, 34 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 6 28 6.5
cell membrane format 1 6 5.3
single protein format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine